Figure 3.
Comparison of the occurrence of major bleeding and/or death within 28 days of randomization. The data of the 2 trial arms are expressed as observed incidence (A), odds ratios (B), and risk differences (C) for the included preterm neonates with severe thrombocytopenia in each of the 4 quartiles of their baseline risks (very low, <13%; low, 13%-16%; intermediate, 17%-24%; and high, >24%). Vertical lines represent 95% CI. Horizontal lines represent the previously published overall trial result, applicable to the nonexisting “average patient.” (A) In all 4 quartiles of baseline risk, the event rates of major bleeding and/or death among patients in the 25 × 109/L intervention arm were lower than the event rates in the 50 × 109/L intervention arm. (B) In all 4 quartiles of baseline risk, the ORs comparing patients in the 50 × 109/L intervention arm with those in the 25 × 109/L arm of the trial are similar. The horizontal line indicates the overall trial result (OR, 1.57). (C) In all 4 quartiles of baseline risk, the risk differences (incidence in the 25 × 109/L arm − incidence in the 50 × 109/L arm) and a horizontal line indicating the overall trial result (−7% absolute-risk difference). The absolute-risk difference indicated harm of the 50 × 109/L transfusion trigger in all 4 quartiles of baseline risk, which was less pronounced among patients with the very low baseline risk, compared with patients with the highest baseline risk.

Comparison of the occurrence of major bleeding and/or death within 28 days of randomization. The data of the 2 trial arms are expressed as observed incidence (A), odds ratios (B), and risk differences (C) for the included preterm neonates with severe thrombocytopenia in each of the 4 quartiles of their baseline risks (very low, <13%; low, 13%-16%; intermediate, 17%-24%; and high, >24%). Vertical lines represent 95% CI. Horizontal lines represent the previously published overall trial result, applicable to the nonexisting “average patient.” (A) In all 4 quartiles of baseline risk, the event rates of major bleeding and/or death among patients in the 25 × 109/L intervention arm were lower than the event rates in the 50 × 109/L intervention arm. (B) In all 4 quartiles of baseline risk, the ORs comparing patients in the 50 × 109/L intervention arm with those in the 25 × 109/L arm of the trial are similar. The horizontal line indicates the overall trial result (OR, 1.57). (C) In all 4 quartiles of baseline risk, the risk differences (incidence in the 25 × 109/L arm − incidence in the 50 × 109/L arm) and a horizontal line indicating the overall trial result (−7% absolute-risk difference). The absolute-risk difference indicated harm of the 50 × 109/L transfusion trigger in all 4 quartiles of baseline risk, which was less pronounced among patients with the very low baseline risk, compared with patients with the highest baseline risk.

Close Modal

or Create an Account

Close Modal
Close Modal